

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10570229	
	Filing Date		2006-02-28	
	First Named Inventor		Biggadike et al.	
	Art Unit		1624	
	Examiner Name		Berch, Mark L.	
	Attorney Docket Number		PB60476USw	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² ⁴	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	0325460	EP				
	2	0434450	EP				
	3	0628044	EP				

T⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10570229
Filing Date	2006-02-28
First Named Inventor	Biggadike et al.
Art Unit	1624
Examiner Name	Berch, Mark L.
Attorney Docket Number	PB60476USw

4	0741710	EP	<input type="checkbox"/>
5	95/21161	WO	<input type="checkbox"/>
6	98/52949	WO	<input type="checkbox"/>
7	99/19327	WO	<input type="checkbox"/>
8	00/19327	WO	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Berge et al., "Pharmaceutical Salts", J. of Pharm. Sci. Vol. 66(1), pp. 1-19, 1977	<input type="checkbox"/>
	2	Daluge et al., "An Efficient, Scalable synthesis of theh HIV Reverse Transcriptase Inhibitor Ziagen® (1592U89)", Nucleosides, Nucleotides & Nucleic Acids, Vol. 19, pp. 297-327, 2000	<input type="checkbox"/>
	3	Fleisher et al., "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews, Vol 19, pp. 115-130, 1996	<input type="checkbox"/>
	4	Legraverend et al., "Synthesis of a New Series of Purine Derivatives and their Anti-Cyclin-Dependent Kinase Activities", J. Heterocyclic Chem., Vol 38, pp. 299-303, 2001	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number	10570229
	Filing Date	2006-02-28
	First Named Inventor	Biggadike et al.
	Art Unit	1624
	Examiner Name	Berch, Mark L.
	Attorney Docket Number	PB60476USw

5	Pederson, et al., "Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide", Diabetes, Vol. 47, pp. 1253-1258, 1998	<input type="checkbox"/>
6	Vince and Hua, "Synthesis and Anti-HIV Activity of Carbocyclic 2',3'-Didehydro-2',3'-dideoxy 2, 6-Disubstituted Purine Nucleosides" J. Med. Chem., Vol. 33, pp. 17-21, 1990	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	
<small> ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. </small>	